NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 240 filers reported holding NEKTAR THERAPEUTICS in Q3 2021. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $317 | -15.9% | 99 | 0.0% | 0.00% | – |
| Q2 2022 | $377 | -29.4% | 99 | 0.0% | 0.00% | – |
| Q1 2022 | $534 | -60.1% | 99 | 0.0% | 0.00% | – |
| Q4 2021 | $1,338 | -24.8% | 99 | 0.0% | 0.00% | -100.0% |
| Q3 2021 | $1,779 | +4.7% | 99 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $1,699 | -14.2% | 99 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $1,980 | +17.6% | 99 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $1,683 | +2.5% | 99 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $1,642 | -28.4% | 99 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $2,293 | +29.8% | 99 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $1,767 | -17.3% | 99 | 0.0% | 0.00% | -50.0% |
| Q4 2019 | $2,137 | +18.5% | 99 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $1,803 | – | 99 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |